Last reviewed · How we verify
Perioperative FOLFOX
FOLFOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to kill rapidly dividing cancer cells.
FOLFOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.
At a glance
| Generic name | Perioperative FOLFOX |
|---|---|
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The combination of these drugs works synergistically to inhibit thymidylate synthase, interfere with DNA replication, and induce DNA damage, ultimately leading to cell death. Oxaliplatin also causes DNA damage through the formation of platinum-DNA adducts.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colon cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Neuropathy
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (PHASE3)
- Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS) (PHASE2)
- Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial (PHASE2)
- FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) (PHASE3)
- Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC (PHASE2)
- The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): (PHASE1, PHASE2)
- Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perioperative FOLFOX CI brief — competitive landscape report
- Perioperative FOLFOX updates RSS · CI watch RSS
- Sixth Affiliated Hospital, Sun Yat-sen University portfolio CI